Pharvaris N.V.
PHVS
$0.56
Change (1 day)
$33.00
Year High
$15.37
Year Low
Categories
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Pharvaris N.V. (PHVS) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 1.04 M | -390,992,732 | 14.65 M | 398.69 M | 397.85 M |
| 2022 | 382.47 K | -161,400,607 | 18.47 M | 167.73 M | 166.85 M |
| 2021 | 700.08 K | -209,102,948 | 7.14 M | 212.09 M | 211.57 M |
| 2020 | 569.58 K | -98,628,871 | 5.31 M | 101.1 M | 100.95 M |
| 2019 | 210.84 K | -20,326,372 | 1.92 M | 20.6 M | 20.58 M |